This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Abi-Habib, R. J. Articles by Frankel, A. E. Search for Related Content PubMed PubMed Citation Articles by Abi-Habib, R. J. Articles by Frankel, A. E.

Departments of ¹ Biochemistry and Molecular Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; ² Hematology/Oncology and Cancer Research Institute, Scott & White Hospital, Temple, Texas; ³ Microbial Pathogenesis Section, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland; and ⁴ Van Andel Research Institute, Grand Rapids, Michigan

Requests for reprints: Arthur E. Frankel, Scott & White Hospital, 2401 South 31st Street, Temple, TX 76508. Phone: 512-724-0094; Fax: 512-724-0098. E-mail: afrankel{at}swmail.sw.org

Anthrax lethal toxin, composed of protective antigen and lethal factor, was tested for cytotoxicity to human melanoma cell lines and normal human cells. Eleven of 18 melanoma cell lines were sensitive to anthrax lethal toxin (IC₅₀ < 400 pmol/L) and 10 of these 11 sensitive cell lines carried the V599E BRAF mutation. Most normal cell types (10 of 15) were not sensitive to anthrax lethal toxin and only 5 of 15 normal human cell types were sensitive to anthrax lethal toxin (IC₅₀ < 400 pmol/L). These cells included monocytes and a subset of endothelial cells. In both melanoma cell lines and normal cells, anthrax toxin receptor expression levels did not correlate with anthrax lethal toxin cytotoxicity. Furthermore, an anthrax toxin receptor–deficient cell line (PR230) did not show any enhanced sensitivity to anthrax lethal toxin when transfected with anthrax toxin receptor. Anthrax lethal toxin toxicity correlated with elevated phosphorylation levels of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) 1/2 in both melanoma cell lines and normal cells. Anthrax lethal toxin–sensitive melanoma cell lines and normal cells had higher phospho-MEK1/2 levels than anthrax lethal toxin–resistant melanoma cell lines and normal tissue types. U0126, a specific MEK1/2 inhibitor, was not toxic to anthrax lethal toxin–resistant melanoma cell lines but was toxic to 8 of 11 anthrax lethal toxin–sensitive cell lines. These results show that anthrax lethal toxin toxicity correlates with elevated levels of active MEK1/2 pathway but not with anthrax toxin receptor expression levels in both normal and malignant tissues. Anthrax lethal toxin may be a useful therapeutic for melanoma patients, especially those carrying the V599E BRAF mutation with constitutive activation of the mitogen-activated protein kinase pathway.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

⁵ R.J. Abi-Habib et al., unpublished observations.

Received 5/ 9/05; revised 6/26/05; accepted 7/ 8/05.